1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

Awaiting development [GID-TA11438] Expected publication date: TBC

  • Project information
  • Project documents

NIHRIO BN: 29556-Cabozantinib-Atezolizumab-for-Castration-Resistant-Prostate-Cancer-V1.0-SEP2023-NON-CONF.pdf (nihr.ac.uk)